Researchers from The Tulane University Center for Stem Cell Research and Regenerative Medicine have developed a new treatment that uses stem cells to control inflammation in patient’s with diabetes.
The modified mesenchymal stem cells (MSC’s) were capable of turning off the inflammatory response which results from neuropathies in the bodies of diabetic patients. Inflammation caused by severe neuropathy can cause excruciating pain in the extremities; hands and feet. It is estimated that this condition affects about 70% of those with diabetes in the U.S.
The unique properties of MSCs and their ability modulate the immune/response systems and to differentiate into a wide range of tissue types such as insulin producing pancreatic beta cells, bone, fat and cartilage make them a suitable source of stem cells for emerging regenerative treatments for a broad range of disease, trauma, and injury.
The safest form of stem cell therapy will involve the use of one’s own stem cells, as these cells are the only ones guaranteed to be a genetic match for the patient. These cells are referred to as autologous stem cells.
To view the full article, click here
The future of Regenerative Medicine is now™.